|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | Mycophenolate mofetil for maintenance of remission in steroid-dependent autoimmune pancreatitis显示文摘Systemic corticosteroids represent the standard treatment for autoimmune pancreatitis with IgG4-associated cholangitis.For steroid-dependent disease,azathioprine has been used for maintenance of remission.Mycophenolate mofetil has been used for transplant immunosuppression and more recently for autoimmune hepatitis;however,there are no case reports to date on the use of mycophenolate mofetil in adult patients with autoimmune pancreatitis.A patient with IgG4-mediated autoimmune pancreatitis and IgG4-associated cholangitis refractory to steroids and intolerant of azathioprine was treated with mycophenolate mofetil,which inhibits de novo guanosine synthesis and blockade of both B and T lymphocyte production.Introduction of mycophenolate mofetil and uptitration to 1000 mg by mouth twice daily over a treatment period of 4 mo was associated with improvement in the patient's energy level and blood glucose control and was not associated with any adverse events.The patient was managed without a biliary stent.However,there was a return of symptoms,jaundice,increase in transaminases,and hyperbilirubinemia when the prednisone dose reached 11 mg per day.In the first report of mycophenolate mofetil use in an adult patient with IgG4-associated autoimmune pancreatitis and IgG4-associated cholangitis,the introduction of mycophenolate mofetil was safe and well-tolerated without adverse events,but it did not enable discontinuation of the steroids.Mycophenolate mofetil and other immunomodulatory therapies should continue to be studied for maintenance of remission in the large subset of patients with refractory or recurrent autoimmune pancreatitis. | Jamie B Sodikoff Steven A Keilin Sheila J Bharmal Melinda M Lewis Gottumukkala S Raju Field F Willingham | 2012 | World Journal of Gastroenterology2012，18，18： | 6 |
| 3 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 4 | Robust Adaptive Control of Induction Motors Without Flux Measurment显示文摘 | Kwan C M Lewis F L Yeung K S | 1995 | ACC1995，32，6： | 1 |
| 5 | Thiazolo pyrimidines: 1 : synthesis and anti-human cytomegalovirus (HCMV) activity in-vitro of certain alkyl derivatives显示文摘 | Lewis A F Revankar G R Fennewald S M | 1995 | J Heterocycl Chem1995，32，20： | 1 |
| 6 | Super-resolution land cover pattern prediction using a Hopfield neural network 显示文摘 | TATEM A J LEWIS H G ATKINSON P M NIXON M S | 2002 | Remote Sensing of Environment2002，，： | 1 |
| 7 | Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody resp- onse in guinea pigs 显示文摘 | Lewis S Morgan D Grubman M | 1991 | J Virol1991，65，12： | 1 |
| 8 | 120 Hz pulse tube cryocooler for fast cooldown to 50K 显示文摘 | Vanapalli S Lewis M Gan Z | 2007 | Applied Physics Letters2007，90，07： | 1 |
| 9 | The fibrillary glomerulopathies 显示文摘 | Korbet S M Schwartz M M Lewis E J | 1994 | Am J Kidney Dis1994，23，5： | 1 |
| 10 | Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial显示文摘 | Benjamin M Scirica Marc P Bonaca Eugene Braunwald Gaetano M De Ferrari Daniel Isaza Basil S Lewis Felix Mehrhof Piera A Merlini Sabina A Murphy Marc S Sabatine Michal Tendera Frans Van de Werf Robert Wilcox David A Morrow | 2012 | The Lancet . 2012 (9850)2012，，9850： | 1 |
| 11 | Impact of a rbeumatology expert nurse on the wellbeing of patients attending a drug monitoring clinic显示文摘 | Ryan S Hassell A Lewis M | 2006 | J Adv Nurs2006，53，3： | 1 |
| 12 | Modelling through-soil transport of phosphorus to surface waters from livestock agriculture at the field and catchment scale 显示文摘 | MeGechan M B Lewis D R Hooda P S | 2005 | Science of the Total Environment2005，344，13： | 1 |
| 13 | Structure-function relations of heparin-mimetic sulphated xylan-oligosaccharides inhibition of Human Immunodeficiency Virus-1 infectivity in vitro显示文摘 | Stone A L Melton D J Lewis M S | 1998 | GlycoconjugateJournal1998，15，： | 1 |
| 14 | Food:a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke显示文摘 | Lewis S Cranswiek G | 2006 | Health Technal Assess2006，10，2： | 1 |
| 15 | Invasion by extremes: Population spread with variation in dispersal and reproduction显示文摘 | Clark J S Lewis M Horvath L | 2001 | American Naturalist2001，157，： | 1 |
| 16 | Identification and charactcfisafion of the structural and nonstmctural proteins of African horse sickness virus and determination of the genome coding assignments显示文摘 | Grubman M J Lewis S A | 1992 | Virology1992，186，： | 1 |
| 17 | Vertical nitrite fluxes in the oligotrophic ocean显示文摘 | Lewis M R Harrison W G Oakey N S | 1986 | Science1986，234，： | 1 |
| 18 | Effects of alkaline hydrogen peroxide treatment on in vitro degradation of cellulosic substrates by mixed ruminal microorganisms and Bacteroides succinogenes S85显示文摘 | Lewis S M Montgomeryl Garleb K A | 1988 | Appl Environ Microbiol1988，54，： | 1 |
| 19 | Effects of alkaline hydrogen peroxide treatment on in vitro degradation of cellulosic substrates by mixed ruminal microorganisms and bacteroides succinogenes S85显示文摘 | Lewis S M Montgomery L Garleb K A | 1988 | Appl Envion Microbiol1988，54，5： | 1 |
| 20 | Acomparison of baseline and induced DNA damage in human spermatozoa from fertile and infertile men, using a modified comet assay显示文摘 | Hughes C M Lewis S E McKelvey-Martin V J | 1996 | Mol Hum Reprod1996，2，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员